首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1918193

輔助生殖技術市場－2026-2031年預測

Assisted Reproductive Technology Market - Forecast from 2026 to 2031

出版日期: 2026年01月16日 | 出版商:

Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

輔助生殖技術（ART）市場預計將從 2025 年的 335.39 億美元成長到 2031 年的 472.49 億美元，複合年成長率為 5.88%。

輔助生殖技術（ART）市場涵蓋了治療不孕症的先進且快速發展的生殖技術領域，包括體外操作卵子、精子和胚胎的技術。該市場的特點是投入巨大，既有情感因素，也有經濟因素，其驅動力源於患者的迫切需求以及旨在提高成功率和擴大服務覆蓋範圍的持續科學進步。

核心臨床操作流程與治療範圍

輔助生殖技術（ART）是指透過手術採集卵子，在實驗室中與精子結合，然後將形成的胚胎植入子宮或冷凍保存。體外受精（IVF）是輔助生殖技術的基礎和最廣泛應用的技術。輔助生殖技術市場不僅限於IVF，還包括卵胞漿內單一精子注射（ICSI）、胚胎胚胎著床前遺傳學檢測（PGT）、卵子/精子/胚胎冷凍保存以及第三方輔助生殖（卵子/精子捐贈和代孕）等相關技術。這套全面的服務涵蓋了多種不孕症病因，從輸卵管因素和男性不孕症到不明原因不孕症以及與老齡化相關的卵子品質下降。

主要市場成長要素

成長要素是全球不孕症盛行率的不斷上升，而這又是由生活方式和醫療因素的複雜交互作用所造成的。這些因素包括初次生育年齡的成長、卵巢症候群（PCOS）和子宮內膜異位症等疾病發生率的上升、肥胖率的上升以及環境因素。不斷擴大的患者群體對有效的不孕症治療產生了持續的需求。

同時，重要的社會人口結構變化正在重塑患者群體。尤其是在已開發國家，生育年齡延遲的趨勢導致自然生育率下降，增加了對輔助生殖技術（ART）的依賴。此外，社會對其他家庭形式的接受度不斷提高，法律也逐漸認可了包括單親家庭和同性伴侶在內的各種家庭形式，這催生了大規模需要輔助生殖技術服務（通常涉及捐精和代孕）來組建家庭的新患者群體，從而擴大了潛在的市場目標群體。

技術和流程創新是市場成長和差異化的關鍵催化劑。持續改善旨在提高成功率、減輕治療負擔並提升安全性。重點研發領域包括：改進培養基和延時胚胎觀察技術以更好地篩選胚胎；進行全面的基因篩檢以識別卵母細胞和胚胎（PGT-A）；改進玻璃化冷凍技術以提高卵子細胞和胚胎冷凍保存的效率；以及開發更溫和的促排卵通訊協定。諸如體內培養系統（如陰道內培養）等創新技術，體現了使治療更便捷、創傷更小的努力。

社會對不孕症認知的提升以及相關污名的消除，是推動市場擴張的強大動力。專業協會、病患支持團體和生育診所積極進行的教育活動，使不孕症治療成為人們普遍關注的議題，鼓勵更多個人和夫妻儘早尋求評估和治療。這種認知的提升，加上媒體報告的增加，正在推動患者數量和服務需求的成長。

支持性且多元化的監管環境和報銷體係也會影響市場動態。在保險覆蓋範圍廣、公共資金支持體外受精（ART）週期的地區，ART的普及率和使用率顯著更高。不斷演變的第三方輔助生殖和胚胎研究相關法律制度也在影響不同地區市場的服務可近性和商業策略。

區域情勢和趨勢

歐洲是一個成熟且重要的市場，其特點是手術量大、法規結構完善，許多國家都有強大的公共資金和保險覆蓋，這促進了高利用率和競爭格局。

北美憑藉其強大的私人保險市場、較高的自付費用能力以及眾多大型研究和商業實驗室，在技術應用和高價值治療週期方面處於主導。它是PGT（胚胎著床前遺傳學檢測）和卵子冷凍保存等先進技術大規模應用和商業化的先驅地區。

亞太地區因其龐大的人口基數、不斷成長的可支配收入、不孕不育治療醫療旅遊的蓬勃發展以及對不孕不育和輔助生殖技術（ART）的文化偏見逐漸減少，而被公認為高成長市場。醫療基礎設施的改善和大型連鎖不孕症診所的興起正在加速該地區的市場發展。

競爭格局與策略重點

競爭環境是多方面的，包括大型上市的生育診所連鎖機構、獨立且成功率高的診所、專門從事生育治療藥物的製藥公司以及專業實驗室設備和耗材的製造商。

策略競爭的重點在於提供卓越的臨床結果（活產率）、優質的病患體驗和全面的服務。領先的診所大力投資先進的實驗室技術，聘請知名的胚胎學家，並提供包括遺傳學、捐卵計畫和代孕協調在內的綜合服務。此外，透過收購和建構整合網路來拓展地域範圍，也是提升市場佔有率的策略重點。

未來市場趨勢

輔助生殖技術（ART）市場的未來發展方向是更個人化、更深入的遺傳學知識和更高的效率。將人工智慧（AI）和機器學習應用於胚胎選擇和週期預測是一項重要的前沿技術。透過粒線體替代療法和體外精子發生等技術來緩解老齡化相關性不孕症的研究，則指向一個更長遠的未來。

市場成長也將受到提高可負擔性和可及性的努力的推動，這些努力包括透過成本控制治療模式、擴大保險覆蓋範圍和簡化技術，然而，圍繞基因選擇、胚胎處置和第三方輔助生殖的複雜倫理、法律和社會問題仍需繼續解決。

行業相關人員的成功取決於保持技術領先地位、提供富有同情心且有效的患者照護，以及應對日益激烈的全球競爭和監管環境。隨著社會趨勢持續向高齡生產和家庭結構多樣化發展，在人類持久的願望和生殖醫學科學技術的不斷進步的推動下，輔助生殖技術（ART）市場預計將繼續擴張。

本報告的主要優勢：

深入分析：獲得主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用這些見解，在動態環境中做出策略決策，並開拓新的商機和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

它是用來做什麼的？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

2022年至2024年的歷史數據和2025年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區（包括國家）分類的收入和預測評估
公司概況（策略、產品、財務資訊、關鍵發展等）

介紹
北美洲
- 透過技術
- 透過治療
- 最終用戶
- 按國家/地區
  - 美國
  - 加拿大
  - 墨西哥
南美洲
- 透過技術
- 透過治療
- 最終用戶
- 按國家/地區
  - 巴西
  - 阿根廷
  - 其他
歐洲
- 透過技術
- 透過治療
- 最終用戶
- 按國家/地區
  - 英國
  - 德國
  - 法國
  - 西班牙
  - 其他
中東和非洲
- 透過技術
- 透過治療
- 最終用戶
- 按國家/地區
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 其他
亞太地區
- 透過技術
- 透過治療
- 最終用戶
- 按國家/地區
  - 中國
  - 日本
  - 印度
  - 韓國
  - 台灣
  - 其他

第9章競爭格局與分析

主要企業和策略分析
市佔率分析
合併、收購、協議和合作
競爭對手儀錶板

第10章：公司簡介

FUJIFILM Irvine Scientific
Merck KGaA
Vitrolife AB
CooperSurgical, Inc.
Thermo Fisher Scientific Inc.
Cook Medical
Genea Biomedx
IMV Technologies
Ferring Pharmaceuticals
IVFtech ApS

第11章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
調查方法
簡稱

簡介目錄

Product Code: KSI061616022

Assisted Reproductive Technology Market, with a 5.88% CAGR, is forecasted to expand from USD 33.539 billion in 2025 to USD 47.249 billion in 2031.

The assisted reproductive technology (ART) market encompasses a sophisticated and rapidly evolving segment of reproductive medicine dedicated to treating infertility through laboratory-based manipulation of eggs, sperm, and embryos. This market is characterized by high emotional and financial investment, driven by profound patient need and continuous scientific advancement aimed at improving success rates and expanding access.

Core Clinical Procedures and Treatment Spectrum

ART refers to procedures where eggs are surgically retrieved, combined with sperm in a laboratory setting, and the resulting embryo(s) are transferred to the uterus or cryopreserved. In-vitro fertilization (IVF) is the cornerstone and most prevalent ART procedure. The market extends beyond IVF to include associated technologies such as intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), egg/sperm/embryo cryopreservation, and third-party reproduction (donor eggs/sperm, gestational surrogacy). This comprehensive suite of services addresses a wide range of infertility etiologies, from tubal factors and male factor infertility to unexplained infertility and age-related decline in oocyte quality.

Primary Market Growth Drivers

A fundamental and persistent driver is the rising global prevalence of infertility, attributed to a complex interplay of lifestyle and medical factors. These include increasing maternal age at first conception, higher rates of conditions like polycystic ovary syndrome (PCOS) and endometriosis, rising obesity levels, and environmental factors. This expanding patient base creates sustained demand for effective fertility treatments.

Concurrent with this, significant sociodemographic shifts are reshaping the patient population. The trend toward delayed childbearing, particularly in developed economies, increases reliance on ART as natural fertility declines. Furthermore, growing social acceptance and legal recognition of alternative family structures-including single parents by choice and same-sex couples-are creating new and substantial patient cohorts who require ART services (often with donor gametes or surrogacy) to build families, thereby broadening the market's addressable base.

Technological and procedural innovation is a critical catalyst for market growth and differentiation. Continuous improvements aim to enhance success rates, reduce treatment burden, and improve safety. Key areas of advancement include: refined culture media and time-lapse embryo imaging for better embryo selection; comprehensive genetic screening (PGT-A) to identify euploid embryos; vitrification techniques for highly effective egg and embryo freezing; and the development of milder stimulation protocols. Innovations like in-vivo culture systems (e.g., intravaginal culture) represent efforts to make treatment more accessible and less invasive.

Increased public awareness and destigmatization of infertility are powerful market enablers. Proactive educational efforts by professional societies, patient advocacy groups, and fertility clinics have normalized discussions around fertility treatment, encouraging more individuals and couples to seek evaluation and care earlier. This increased awareness, coupled with growing media coverage, drives patient volumes and demand for services.

Supportive, though varied, regulatory and reimbursement landscapes also influence market dynamics. In regions with favorable insurance mandates or public funding for ART cycles, access and utilization are significantly higher. Evolving legal frameworks governing third-party reproduction and embryo research also shape service availability and commercial strategies across different geographic markets.

Geographic Landscape and Regional Dynamics

Europe represents a mature and significant market, characterized by high procedure volumes, well-established regulatory frameworks, and often substantial public funding or insurance coverage in many countries. This support fosters high utilization rates and a competitive clinic landscape.

North America is a leader in technological adoption and high-value treatment cycles, driven by a robust private-payer market, significant out-of-pocket spending capacity, and a concentration of leading research institutions and commercial laboratories. The region is often the first to adopt and commercialize advanced techniques like PGT and egg freezing on a large scale.

The Asia-Pacific region is identified as a high-growth market, fueled by large populations, rising disposable incomes, increasing medical tourism for fertility services, and gradually decreasing cultural stigma surrounding infertility and ART. Improving healthcare infrastructure and the emergence of large, chain-owned fertility clinics are accelerating market development in this region.

Competitive Landscape and Strategic Focus

The competitive environment is multifaceted, including large publicly-traded fertility clinic chains, independent high-success-rate clinics, pharmaceutical companies specializing in fertility drugs, and manufacturers of specialized laboratory equipment and consumables.

Strategic competition centers on demonstrating superior clinical outcomes (live birth rates), patient experience, and service range. Leading clinics invest heavily in advanced laboratory technologies, recruit renowned embryologists, and offer comprehensive services including genetics, donor programs, and surrogacy coordination. There is also a strategic focus on geographic expansion through acquisition and the development of integrated networks to capture market share.

Future Market Trajectory

The future trajectory of the ART market is oriented toward greater personalization, genetic insight, and efficiency. The integration of artificial intelligence and machine learning for embryo selection and cycle prediction is a major frontier. Research into mitigating age-related infertility, through techniques like mitochondrial replacement or in-vitro gametogenesis, represents a longer-term horizon.

Market growth will also be influenced by efforts to improve affordability and access through cost-contained treatment models, insurance expansion, and technological simplification. However, the market will continue to navigate complex ethical, legal, and social considerations surrounding genetic selection, embryo disposition, and third-party reproduction.

Success for industry participants will depend on maintaining technological leadership, delivering compassionate and effective patient care, and navigating an increasingly competitive and regulated global landscape. As societal trends toward later parenthood and diverse family formation continue, the ART market is poised for sustained expansion, driven by deep-seated human aspirations and the relentless pursuit of scientific progress in reproductive medicine.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2022 to 2024 & forecast data from 2025 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Assisted Reproductive Technology Market Segmentation

By Technique
In Vitro Fertilization (IVF)
Artificial Insemination (AI)
Frozen Embryo Transfer (FET)
Surrogacy
Others
By Procedure
Fresh Donor
Fresh Non-Donor
Frozen Donor
Frozen Non-Donor
By End-User
Hospitals
Fertility Clinics
Cryobanks
Research Institutes
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
India
South Korea
Taiwan
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TECHNIQUE

5.1. Introduction
5.2. In Vitro Fertilization (IVF)
5.3. Artificial Insemination (AI)
5.4. Frozen Embryo Transfer (FET)
5.5. Surrogacy
5.6. Others

6. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY PROCEDURE

6.1. Introduction
6.2. Fresh Donor
6.3. Fresh Non-Donor
6.4. Frozen Donor
6.5. Frozen Non-Donor

7. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY END-USER

7.1. Introduction
7.2. Hospitals
7.3. Fertility Clinics
7.4. Cryobanks
7.5. Research Institutes

8. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. By Technique
- 8.2.2. By Procedure
- 8.2.3. By End-User
- 8.2.4. By Country
  - 8.2.4.1. USA
  - 8.2.4.2. Canada
  - 8.2.4.3. Mexico
8.3. South America
- 8.3.1. By Technique
- 8.3.2. By Procedure
- 8.3.3. By End-User
- 8.3.4. By Country
  - 8.3.4.1. Brazil
  - 8.3.4.2. Argentina
  - 8.3.4.3. Others
8.4. Europe
- 8.4.1. By Technique
- 8.4.2. By Procedure
- 8.4.3. By End-User
- 8.4.4. By Country
  - 8.4.4.1. United Kingdom
  - 8.4.4.2. Germany
  - 8.4.4.3. France
  - 8.4.4.4. Spain
  - 8.4.4.5. Others
8.5. Middle East and Africa
- 8.5.1. By Technique
- 8.5.2. By Procedure
- 8.5.3. By End-User
- 8.5.4. By Country
  - 8.5.4.1. Saudi Arabia
  - 8.5.4.2. UAE
  - 8.5.4.3. Others
8.6. Asia Pacific
- 8.6.1. By Technique
- 8.6.2. By Procedure
- 8.6.3. By End-User
- 8.6.4. By Country
  - 8.6.4.1. China
  - 8.6.4.2. Japan
  - 8.6.4.3. India
  - 8.6.4.4. South Korea
  - 8.6.4.5. Taiwan
  - 8.6.4.6. Others